10,380 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Bought by Savant Capital LLC

Savant Capital LLC acquired a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,380 shares of the company’s stock, valued at approximately $100,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in MiMedx Group by 1.6% during the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock worth $16,518,000 after purchasing an additional 44,254 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of MiMedx Group by 6.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after acquiring an additional 92,726 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after acquiring an additional 770,744 shares during the last quarter. Royce & Associates LP grew its position in shares of MiMedx Group by 5.3% in the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after purchasing an additional 48,539 shares during the period. Finally, Disciplined Growth Investors Inc. MN grew its position in shares of MiMedx Group by 0.8% in the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock valued at $2,100,000 after purchasing an additional 2,737 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Price Performance

MDXG stock opened at $8.06 on Thursday. The stock has a 50-day moving average price of $8.89 and a two-hundred day moving average price of $7.62. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.18 billion, a PE ratio of 14.65 and a beta of 1.94.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.